BMC Pulmonary Medicine (Mar 2024)

Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study– few concerns

  • Divya Balan,
  • Manish R Shetty,
  • Manu K Mohan

DOI
https://doi.org/10.1186/s12890-024-02951-9
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 2

Abstract

Read online

Abstract This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio, however it did not offer novel insights, as both agents met the 12%- and 200-mL reversibility benchmarks and Concerns about incorporating a combination medication that includes an inhaled corticosteroid, inhaled corticosteroids are not typically associated with bronchodilation.